Robert C. Goeltz II's Net Worth
$1.65 Million
Who is Robert C. Goeltz II?
Robert C. Goeltz II has an estimated net worth of $1.65 Million. This is based on reported shares across multiple companies, which include Arcus Biosciences, Inc., Unity Biotechnology, Inc., and CytomX Therapeutics, Inc..
SEC CIK
Robert C. Goeltz II's CIK is 0001653881
Past Insider Trading and Trends
2017 was Robert C. Goeltz II's most active year for acquiring shares with 6 total transactions. Robert C. Goeltz II's most active month to acquire stocks was the month of December. 2017 was Robert C. Goeltz II's most active year for disposing of shares, totalling 7 transactions. Robert C. Goeltz II's most active month to dispose stocks was the month of November. 2020 saw Robert C. Goeltz II paying a total of $142,148.50 for 412,294 shares, this is the most they've acquired in one year. In 2017 Robert C. Goeltz II cashed out on 68,501 shares for a total of $426,340.00, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Arcus Biosciences, Inc. (RCUS) Snapshot price: $14.87
Chief Financial Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4/A
| +42.45% | 22K |
—
|
—
| 73.83K |
Jan 23
| |||
Form 4
| +41.10% | 21.3K |
—
|
—
| 73.13K |
Jan 23
| |||
Form 4
| -3.72% | -2.00K |
$20.00 | -$40,080.00 | 51.83K |
Scheduled
|
Jan 2
| ||
Form 4
| -9.36% | -5.56K |
$17.92 | -$99,563.98 | 53.84K |
Scheduled
|
Dec 18 - Dec 19
| ||
Form 4
| -6.38% | -4.05K |
$20.04 | -$81,141.96 | 59.39K |
Jun 7
| |||
Form 4
| +115.49% | 34K |
—
|
—
| 63.44K |
Jan 23
| |||
Form 4
| -17.50% | -2.45K |
$30.75 | -$75,429.57 | 11.57K |
Dec 16
| |||
Form 4
| +220.83% | 15.5K |
—
|
—
| 22.52K |
Mar 8
| |||
Form 4
| -13.61% | -1.11K |
$40.12 | -$44,376.01 | 7.02K |
Dec 16 - Dec 17
| |||
Form 4
| +250.00% | 12.5K |
—
|
—
| 17.5K |
Jan 19
| |||
Form 4
|
∞
| 5K |
$21.57 | $107,848.50 | 5K |
Sep 9
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Aug 3
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Unity Biotechnology, Inc. (UBX) Snapshot price: $1.7389
Chief Financial Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -1.52% | -2.48K |
$9.67 | -$24,010.61 | 161.03K |
Jun 22
| |||
Form 4
| +21.66% | 29.11K |
—
|
—
| 163.51K |
Mar 30
| |||
Form 4
| +8.04% | 10K |
$3.43 | $34,300.00 | 134.4K |
Feb 24
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 19
| |||
Form 4
| +20.40% | 21.07K |
—
|
—
| 124.4K |
Jun 20
| |||
Form 4
| +5.19% | 5K |
$3.43 | $17,150.00 | 101.35K |
Oct 10
| |||
Form 4
| +1.72% | 1.63K |
—
|
—
| 96.35K |
May 7
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 2
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
CytomX Therapeutics, Inc. (CTMX) Snapshot price: $1.45
Chief Financial Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +156.13% | 19.97K |
$5.54 | $110,699.55 | 32.76K |
May 12
| |||
Form 4
| +30.65% | 3K |
$4.47 | $13,418.40 | 12.79K |
Apr 10
| |||
Form 4
|
—
|
0
|
$12.14 | -$330,098.76 | 9.79K |
Scheduled
|
Mar 20
| ||
Form 4
| +34.30% | 2.5K |
$4.47 | $11,182.00 | 9.79K |
Mar 9
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 25
| |||
Form 4
| +21.48% | 1.29K |
$9.10 | $11,723.46 | 7.29K |
Nov 30
| |||
Form 4
| +200.00% | 4K |
$4.47 | $17,891.20 | 6K |
Sep 29
| |||
Form 4
|
∞
| 2K |
$4.47 | $8,945.60 | 2K |
May 12
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 21
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||